Vertex Pharmaceuticals Inc (VRTX) bonds

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3026% above fair value

$538.60−4.02 (-0.74%)

Close on Nov 13, 2026Market cap $136.51BP/E 31.4Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

As tagged in Vertex Pharmaceuticals's 10-Q for the period ended Jul 31, 2022

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Revolving credit lines and other committed borrowing capacity

Facility	Size
Letters of Credit	$100.00M
Revolving Credit Facility	$500.00M

Parsed from the XBRL in Vertex Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Aug 24, 2000
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRTX.

Revenue growth10.2% · median 11.4%

Gross margin86.0% · median 64.4%

Operating margin38.0% · median 15.4%

Net margin35.0% · median 28.5%

Advertisement
300 × 250

See a number that looks wrong?